Everolimus (RAD001) ( DrugBank: Everolimus )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
34	神経線維腫症	2
89	リンパ脈管筋腫症	2
158	結節性硬化症	6

34. 神経線維腫症

臨床試験数 : 133 / 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01365468 (ClinicalTrials.gov)	April 2012	27/5/2011	Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromat ...	A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated ...	Plexiform Neurofibroma Associated With Neurofibromatosis Type 1	Drug: Everolimus (RAD001)	Novartis Pharmaceuticals	NULL	Terminated	6 Years	N/A	All	9	Phase 2	Israel
2	NCT01419639 (ClinicalTrials.gov)	October 2011	17/8/2011	Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2	Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2	Neurofibromatosis Type II	Drug: Everolimus (RAD001) , Afinitor®	New York University School of Medicine	Novartis Pharmaceuticals;The Children's Tumor Foundation	Completed	3 Years	N/A	All	10	Phase 2	United States

First Previous1Next Last

89. リンパ脈管筋腫症

臨床試験数 : 38 / 薬物数 : 38 - (DrugBank : 15) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 118

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00790400 (ClinicalTrials.gov)	April 2009	10/11/2008	Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Eithe ...	A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma i ...	Tuberous Sclerosis Complex (TSC);Lymphangioleiomyomatosis (LAM)	Drug: Everolimus (RAD001);Drug: Everolimus Placebo	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	118	Phase 3	United States;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United K ...
2	NCT00792766 (ClinicalTrials.gov)	December 2008	17/11/2008	Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) ...	Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Compl ...	Tuberous Sclerosis;Angiolipoma	Drug: everolimus (RAD001)	Children's Hospital Medical Center, Cincinnati	Novartis	Completed	18 Years	65 Years	Both	20	Phase 1/Phase 2	United States

First Previous1Next Last

158. 結節性硬化症

臨床試験数 : 112 / 薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01954693 (ClinicalTrials.gov)	June 2012	5/9/2013	A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis	TRON: A Randomised, Double Blind, Placebo-controlled Study of RAD001 (Everolimus) in the Treatment o ...	Tuberous Sclerosis	Drug: Placebo;Drug: Everolimus (RAD001)	Cardiff University	Novartis	Unknown status	16 Years	60 Years	All	48	Phase 2	United Kingdom
2	NCT01070316 (ClinicalTrials.gov)	January 2010	15/2/2010	Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex	Epilepsy;Tuberous Sclerosis Complex	Drug: Everolimus	Children's Hospital Medical Center, Cincinnati	Novartis	Completed	2 Years	N/A	All	20	Phase 1/Phase 2	United States
3	NCT00789828 (ClinicalTrials.gov)	August 2009	12/11/2008	Efficacy and Safety of Everolimus (RAD001)in Patients of All Ages With Subependymal Giant Cell Astro ...	A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With ...	Tuberous Sclerosis;Subependymal Giant Cell Astrocytoma	Drug: Everolimus;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	N/A	N/A	All	117	Phase 3	United States;Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Ki ...
4	NCT00790400 (ClinicalTrials.gov)	April 2009	10/11/2008	Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Eithe ...	A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma i ...	Tuberous Sclerosis Complex (TSC);Lymphangioleiomyomatosis (LAM)	Drug: Everolimus (RAD001);Drug: Everolimus Placebo	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	118	Phase 3	United States;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United K ...
5	NCT00792766 (ClinicalTrials.gov)	December 2008	17/11/2008	Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) ...	Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Compl ...	Tuberous Sclerosis;Angiolipoma	Drug: everolimus (RAD001)	Children's Hospital Medical Center, Cincinnati	Novartis	Completed	18 Years	65 Years	Both	20	Phase 1/Phase 2	United States
6	NCT00411619 (ClinicalTrials.gov)	January 2007	12/12/2006	Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex	Everolimus (RAD001)Therapy of Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex	Tuberous Sclerosis;Subependymal Giant Cell Astrocytoma	Drug: Everolimus	Children's Hospital Medical Center, Cincinnati	Novartis	Completed	3 Years	N/A	All	28	Phase 1/Phase 2	United States

First Previous1Next Last

先頭へ